The citation records a peer-reviewed article in Emerg Microbes Infect (Dec 2026 issue) with DOI 10.1080/22221751.2026.2760598 and an electronic publication date of 20 November 2026. The title presented is “Modelling severe COVID-19 by adaptation of SARS-CoV-2 in Syrian hamsters.” Investigators reported authorship by a large multi-institutional team based primarily at The University of Hong Kong and affiliated centres. The PubMed entry provided here contains bibliographic metadata but does not include the study abstract or the paper’s full text within the supplied extract.
Short sentence: publication details are confirmed. Longer sentence: because only the header information and author list were available in the provided source text, the experimental content—methods, results, and interpretive discussion—was not included and therefore cannot be summarized from this excerpt alone.
The author list in the provided record includes multiple named investigators associated with the State Key Laboratory of Emerging Infectious Diseases, the Carol Yu Centre for Infection, and the InnoHK Centre for Virology, Vaccinology and Therapeutics, among other University of Hong Kong units. The source lists institutional affiliations but does not supply corresponding author contact details or specific role assignments for individuals. The publication metadata indicate contributions from laboratories that specialize in virology and infectious diseases, implying relevant domain expertise among the team.
The study’s title states an aim: to model severe COVID-19 by adapting SARS-CoV-2 to Syrian hamsters. That phrase signals two principal elements. First, investigators sought to generate or characterize viral variants or experimental conditions that produce more pronounced disease manifestations in a commonly used small-animal model. Second, the use of Syrian hamsters as the host implies in vivo work designed to mimic clinically significant respiratory disease for mechanistic studies or preclinical testing.
Short factual clause: the title alone cannot convey experiment specifics. Extended clause: without the abstract or methods, the supplied content does not reveal which readouts—clinical scoring systems, respiratory metrics, imaging, virologic load, immunopathology, or survival endpoints—were designated to define severity, nor does it state whether adaptation occurred via serial passaging, targeted mutation, or alternative selective pressures.
The PubMed excerpt here did not include the study’s abstract or any methods and results sections. Consequently, the following items are not reported in the provided text: the adaptation protocol for SARS-CoV-2, animal numbers and demographics, inoculation route and dose, timepoints for sampling, virologic or histopathologic endpoints, quantitative outcomes, statistical analyses, any adverse events observed, and the authors’ interpretation of translational relevance. The supplied record confirms the paper’s existence and provenance but does not permit extraction of experimental findings or performance characteristics of the proposed model.
Short sentence: critical experimental details are absent from this extract. Longer sentence with emphasis: in the absence of primary data in the supplied source, no reliable claims can be made here about the model’s fidelity to human severe COVID-19, its reproducibility, or its suitability for therapeutic or vaccine evaluation.
What defines “severe” in this animal model? The provided text does not say. Did adaptation alter viral tropism, replication kinetics, or host immune responses in ways that emulate human critical illness? The supplied extract does not report such outcomes. Can this model be used to evaluate supportive critical care interventions or candidate therapeutics with predictive validity for humans? The source text here does not address that question.
Short closing sentence: readers must consult the full article. Final longer sentence: to assess the experimental rigor, translational value, and potential limitations of the described work—such as species-specific immune responses, ethical considerations, or biosafety implications—one must review the full manuscript or its abstract, which were not present in the provided PubMed excerpt.